Akari Therapeutics (AKTX) Total Current Liabilities (2011 - 2026)

Akari Therapeutics (AKTX) has 12 years of Total Current Liabilities data on file, last reported at $13.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 35.83% year-over-year to $13.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.4 million (down 35.83% YoY), and the FY2025 full-year result was $12.4 million, down 37.97% from the prior year.
• Total Current Liabilities grew to $13.4 million in Q1 2026, from $12.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $20.9 million in Q1 2025 to a low of $4.6 million in Q4 2023.
• A 4-year average of $12.8 million and a median of $12.9 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 334.34% in 2024 and tumbled 37.97% in 2025, its largest moves.
• Tracing AKTX's Total Current Liabilities over 4 years: stood at $4.6 million in 2023, then jumped by 334.34% to $19.9 million in 2024, then plunged by 37.97% to $12.4 million in 2025, then increased by 8.61% to $13.4 million in 2026.
• Business Quant data shows AKTX's Total Current Liabilities at $13.4 million in Q1 2026, $12.4 million in Q4 2025, and $15.6 million in Q3 2025.